http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102046435-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-988 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-20 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2013-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102046435-B1 |
| titleOfInvention | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
| abstract | Antibodies that bind GCC and antigen-binding fragments of antibodies are disclosed. The invention also provides a diagnostic method for identifying a patient who is to receive a GCC-targeted therapy using the anti-GCC antibodies provided herein. Anti-GCC antibody molecules are useful as naked antibody molecules and as components of an immunoconjugate. Thus in another aspect, the invention features an immunoconjugate comprising an anti-GCC antibody molecule described herein and a therapeutic agent or label. The invention also features methods of using the anti-GCC antibody molecules and immunoconjugates described herein for the detection of GCC and cells or tissues expressing GCC, for example. Such methods are particularly useful for the diagnosis, prognosis, contrast or stage of GCC-mediated disease. Thus, in some aspects, the invention features a method of identifying a subject for treatment with a GCC-targeted therapy, eg an anti-GCC antibody therapy, eg, an immunoconjugate comprising an anti-GCC antibody conjugated with a therapeutic agent. |
| priorityDate | 2012-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1786.